Novo increases fatty liver efforts: "We've seen some highly convincing data"
![Novo Nordisk Executive Vice President, Development Martin Holst Lange | Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12843848.ece/ALTERNATES/schema-16_9/doc7eyu74vvsgi15yjfzavt.jpg)
Danish pharmaceutical company Novo Nordisk keeps powering ahead in its efforts to find the first drug in the world which can treat the serious fatty liver disease non-alcoholic steatohepatitis (NASH).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk and Gilead expand partnership
For subscribers